Skip to main content
PAS 2025 Meeting Main banner
Final Program


Schedule at a Glance
Icon Legend
Back

Cardiology

Cardiology 1

Cardiovascular-Kidney-Metabolic Syndrome is Associated with Worse Blood Pressure Severity but Not Target Organ Injury at Baseline in Youth Referred for HTN Disorders: A SUPERHERO Analysis

Sunday, April 27, 2025
7:15am – 7:30am HST
Location:  Convention Center: 319
Andrew M. South, Wake Forest School of Medicine of Wake Forest Baptist Medical Center, Winston Salem, NC, United States; Rushelle Byfield, NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY, United States; Jessica Fallon. Campbell, Baylor College of Medicine, Houston, TX, United States; Giya Harry, Wake Forest School of Medicine, Winston salem, NC, United States; Margaret Murphy, University of Kentucky College of Medicine, Lexington, KY, United States; Elizabeth A. Onugha, Baylor College of Medicine, Houston, TX, United States; Ashna Pudupakkam, Baylor College of Medicine, Houston, TX, United States; Sandeep Riar, Children's Healthcare of Atlanta, Atlanta, GA, United States; Landon T. Sanz, Wake Forest School of Medicine of Wake Forest Baptist Medical Center, Spring, TX, United States; Sahar Siddiqui, Texas Children's Hospital, Houston, TX, United States; Michael J. Walsh, Wake Forest School of Medicine of Wake Forest Baptist Medical Center, Winston-Salem, NC, United States; Carol Vincent, Wake Forest Baptist Health - Brenner Children's Hospital, Winston Salem, NC, United States

    Presenting Author(s)

  • Andrew M. South, MD, MS (he/him/his)

    Associate Professor
    Wake Forest University School of Medicine
    Winston Salem, North Carolina, United States

Disclosure(s):
Andrew M. South, MD, MS: Conjupro Biotherapeutics, Inc. (Terminated, June 15, 2023) (Products/Services: Consultant, Consultant); IDORSIA Pharmaceuticals US, Inc. (Terminated, September 4, 2024) (Products/Services: Advisory Committee); Kyowa Kirin Co., Ltd. (Terminated, August 10, 2024) (Products/Services: Advisory Committee); MJH Life Sciences (Terminated, October 25, 2024) (Products/Services: Advisory Committee)